Advanced Imaging Techniques in Parkinson's Disease Research

Author: Manolo E. Beelke

Email: [email protected]

Web: manolobeelke.com

Abstract

This article explores the advanced imaging techniques employed in Parkinson's Disease (PD) research, emphasizing their critical role in enhancing diagnosis, monitoring disease progression, and evaluating therapeutic interventions. By providing a comprehensive review of historical developments and recent advancements in imaging technologies, this article illustrates how these tools have revolutionized our understanding of PD. Special attention is given to the application of imaging in clinical trials, particularly in Phase 2 and Phase 3 studies, where imaging can serve as a surrogate marker, potentially reducing the burden of frequent visits while increasing the sensitivity and specificity of trial outcomes. The article concludes with a discussion of future research directions and the ethical considerations inherent in imaging research, along with a patient-centric perspective on the use of these technologies.

Introduction

Parkinson’s Disease (PD) is a complex, progressive neurodegenerative disorder that primarily affects movement, causing symptoms such as tremors, rigidity, and bradykinesia. In addition to these motor symptoms, PD is also associated with a range of non-motor symptoms, including cognitive impairment, mood disorders, and autonomic dysfunction. The multifaceted nature of PD makes diagnosis and management particularly challenging, necessitating the use of advanced diagnostic and monitoring tools.

Imaging techniques have emerged as crucial tools in the diagnosis and management of PD, offering detailed insights into the structural and functional changes that occur in the brain. These techniques not only aid in the early diagnosis of the disease but also play a vital role in monitoring its progression and evaluating the efficacy of therapeutic interventions. Over the past few decades, significant advancements in imaging technologies have transformed our understanding of PD, enabling more accurate diagnoses and more effective treatments.

This article provides an in-depth review of the various imaging techniques currently used in PD research and clinical practice. It also discusses the historical development of these techniques, their role in the diagnosis of PD, and their application in clinical trials. Additionally, the article explores the potential of imaging-based surrogate biomarkers in PD and considers the future directions of imaging research, with a focus on the ethical considerations and patient perspectives that are essential to the successful implementation of these technologies.

Advanced Imaging Techniques in Parkinson’s Disease Research

Imaging techniques have revolutionized Parkinson's Disease research by providing detailed insights into the brain's structural and functional changes. These technologies have become indispensable tools for early diagnosis, disease monitoring, and the evaluation of therapeutic interventions. As PD progresses, it causes significant changes in brain structure and function, particularly in regions involved in movement control, such as the substantia nigra. Imaging allows researchers and clinicians to visualize these changes, facilitating a better understanding of the disease and improving patient care.

One of the most significant advancements in PD research has been the development of advanced magnetic resonance imaging (MRI) techniques. MRI provides high-resolution images of brain structures, allowing researchers to detect subtle changes in brain anatomy that may indicate the onset or progression of PD. Functional MRI (fMRI) and diffusion tensor imaging (DTI), two advanced forms of MRI, have further expanded our understanding of the brain's functional connectivity and white matter integrity in PD.

Positron emission tomography (PET) and single photon emission computed tomography (SPECT) are nuclear imaging techniques that have also played a critical role in PD research. These techniques use radioactive tracers to visualize metabolic processes and neurotransmitter systems in the brain. PET, in particular, has been instrumental in studying the dopaminergic system, which is severely affected in PD. Recent advancements in PET imaging have enabled the visualization of other molecular targets, such as alpha-synuclein and tau, which are involved in the pathogenesis of PD.

Another important imaging modality in PD research is transcranial sonography (TCS), a form of ultrasound imaging. TCS is a non-invasive technique that can detect hyperechogenicity in the substantia nigra, a hallmark of PD. This technique is valuable for early diagnosis and differentiation of PD from other movement disorders.

In addition to these established imaging techniques, emerging technologies such as optical coherence tomography (OCT) and photoacoustic imaging are being explored for their potential to provide high-resolution images of brain structures and monitor disease progression. Molecular imaging, which uses imaging probes to visualize specific molecular targets in the brain, is also becoming increasingly important in PD research, offering deep insights into the molecular mechanisms driving the disease.

Overall, imaging techniques have significantly enhanced our understanding of Parkinson's Disease. They have provided researchers and clinicians with powerful tools to visualize the brain's structural and functional changes, enabling more accurate diagnoses, better monitoring of disease progression, and more effective evaluation of therapeutic interventions (Mahlknecht et al., 2017).The history of imaging in Parkinson’s Disease dates back to the early days of radiology, when X-ray techniques were first used to visualize the brain. However, these early imaging methods provided limited information about the brain’s complex structures and were not particularly useful in diagnosing or understanding neurodegenerative diseases like PD. It was not until the development of computed tomography (CT) and magnetic resonance imaging (MRI) that significant progress was made in the field of neuroimaging.

CT, introduced in the 1970s, was a breakthrough in medical imaging, allowing for detailed cross-sectional images of the brain. However, its application in PD was limited because it primarily visualized bone structures and could not provide sufficient detail about the soft tissues of the brain. MRI, which became widely available in the 1980s, offered a significant improvement. Using powerful magnetic fields and radio waves, MRI could generate high-resolution images of the brain's soft tissues, making it possible to detect structural abnormalities associated with PD.

The advent of functional MRI (fMRI) and diffusion tensor imaging (DTI) in the 1990s further expanded the capabilities of MRI. fMRI allows researchers to study brain activity by measuring changes in blood flow, while DTI provides information about the integrity of white matter tracts, which are crucial for communication between different brain regions. These advanced MRI techniques have been particularly useful in PD research, providing insights into the functional and structural connectivity of the brain and helping to identify early changes that may precede the onset of motor symptoms.

In parallel with the development of MRI, nuclear imaging techniques such as positron emission tomography (PET) and single photon emission computed tomography (SPECT) were also making significant strides. These techniques, which use radioactive tracers to visualize metabolic processes and neurotransmitter systems in the brain, have been invaluable in studying the dopaminergic system, which is heavily impacted in PD. PET, in particular, has provided critical insights into the loss of dopamine-producing neurons in the substantia nigra, one of the key pathological features of PD.

Over the years, the focus of imaging in PD has shifted from simply identifying structural abnormalities to understanding the functional and molecular changes that occur in the brain. This shift has been driven by ongoing advancements in imaging technology, which have allowed researchers to visualize not just the brain’s anatomy but also its function and biochemistry. Today, imaging plays a central role in PD research, helping to unravel the complex pathophysiology of the disease and paving the way for new diagnostic and therapeutic strategies (Brooks, 2016).

The Role of Imaging in Parkinson’s Disease Diagnosis

Imaging techniques have become integral to the diagnosis of Parkinson’s Disease, complementing traditional clinical evaluations and enhancing diagnostic accuracy. PD is primarily diagnosed based on clinical symptoms, such as bradykinesia, rigidity, and resting tremor. However, these symptoms can overlap with those of other neurodegenerative disorders, such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), making differential diagnosis challenging. Imaging plays a crucial role in distinguishing PD from these other conditions, providing additional information that can help confirm the diagnosis.

Magnetic resonance imaging (MRI) is one of the most commonly used imaging modalities in PD diagnosis. While conventional MRI is not typically used to diagnose PD, it is often employed to rule out other conditions that can mimic PD, such as stroke or brain tumors. More advanced MRI techniques, such as diffusion tensor imaging (DTI) and susceptibility-weighted imaging (SWI), can detect subtle changes in the brain's white matter and iron deposition in the substantia nigra, respectively. These changes may serve as biomarkers for PD and can help differentiate it from other parkinsonian syndromes.

Positron emission tomography (PET) and single photon emission computed tomography (SPECT) are nuclear imaging techniques that have been particularly useful in diagnosing PD. PET and SPECT can visualize the dopaminergic system, which is significantly affected in PD. For instance, PET imaging with the radiotracer [^18F]-fluorodopa (FDOPA) can measure dopamine synthesis in the brain, while SPECT imaging with the radiotracer [^123I]-ioflupane (DaTSCAN) can assess dopamine transporter (DAT) binding. Reduced uptake of these tracers in the striatum is indicative of dopaminergic neuron loss and is a hallmark of PD.

In addition to helping with diagnosis, imaging techniques can also provide valuable information about the severity and progression of PD. For example, changes in the uptake of PET or SPECT tracers over time can reflect the ongoing loss of dopaminergic neurons, offering insights into the disease's progression. This information can be crucial for tailoring treatment strategies to the individual patient's needs.

Furthermore, imaging can aid in the early diagnosis of PD, potentially before the onset of motor symptoms. Research has shown that imaging techniques such as MRI and PET can detect structural and functional changes in the brain that occur in the prodromal stage of PD, when non-motor symptoms like olfactory dysfunction, sleep disturbances, and constipation are present. Early diagnosis is essential for implementing neuroprotective therapies that could slow or halt disease progression.

Overall, imaging techniques have greatly enhanced the diagnostic process for Parkinson’s Disease, providing clinicians with powerful tools to confirm the diagnosis, assess disease severity, and monitor progression. As imaging technology continues to advance, it is likely to play an increasingly important role in the early diagnosis and management of PD (Postuma et al., 2015).

Magnetic Resonance Imaging (MRI)

Magnetic resonance imaging (MRI) is a cornerstone of neuroimaging in Parkinson’s Disease research, offering detailed images of the brain's anatomy and providing critical insights into the structural changes associated with the disease. MRI is a non-invasive imaging technique that uses powerful magnetic fields and radio waves to generate high-resolution images of soft tissues, making it particularly well-suited for studying the brain.

In Parkinson’s Disease, MRI is used primarily to detect structural changes in the brain, such as atrophy in specific regions. One of the key areas of interest in PD research is the substantia nigra, a region of the brain that is heavily involved in the control of movement and is one of the first areas to be affected by the disease. In advanced stages of PD, the substantia nigra undergoes significant atrophy, which can be detected by MRI. However, even in the early stages of the disease, subtle changes in the structure of the substantia nigra can be observed using advanced MRI techniques.

One such technique is diffusion tensor imaging (DTI), which measures the diffusion of water molecules in brain tissue. DTI provides information about the integrity of white matter tracts, which are crucial for communication between different brain regions. In PD, DTI has been used to study changes in white matter integrity in the substantia nigra and other brain regions. Studies have shown that DTI can detect early changes in white matter that are associated with PD, making it a valuable tool for early diagnosis and monitoring disease progression (Zhang et al., 2015).

Another advanced MRI technique is functional MRI (fMRI), which measures brain activity by detecting changes in blood flow. fMRI is particularly useful for studying the functional connectivity of brain networks involved in motor control and cognitive functions. In PD, fMRI has been used to identify alterations in brain activity associated with the disease, such as reduced connectivity between the basal ganglia and the motor cortex. These changes in functional connectivity are thought to underlie the motor symptoms of PD, such as bradykinesia and tremor.

In addition to studying structural and functional changes in the brain, MRI can also be used to detect changes in brain biochemistry. For example, magnetic resonance spectroscopy (MRS) is an MRI technique that can measure the concentration of various metabolites in the brain. In PD, MRS has been used to study changes in the levels of neurotransmitters such as glutamate and GABA, as well as markers of oxidative stress and mitochondrial dysfunction.

Overall, MRI is an essential tool in Parkinson’s Disease research, providing detailed information about the brain's structure, function, and biochemistry. As MRI technology continues to advance, it is likely to play an even more significant role in the diagnosis and management of PD, helping to identify early changes in the brain and monitor the effects of therapeutic interventions (Schwarz et al., 2018).Functional magnetic resonance imaging (fMRI) is a powerful tool in Parkinson’s Disease research, offering a non-invasive method to study brain activity and functional connectivity. Unlike traditional MRI, which provides static images of the brain's structure, fMRI measures dynamic changes in blood flow, allowing researchers to observe how different brain regions interact during various tasks. This capability is particularly valuable in studying PD, a disease characterized by disruptions in motor and cognitive functions.

In Parkinson’s Disease, fMRI is used to investigate the functional connectivity of brain networks involved in motor control, such as the cortico-basal ganglia-thalamo-cortical loop. This network plays a crucial role in the initiation and execution of movement, and its dysfunction is a hallmark of PD. fMRI studies have shown that PD patients exhibit reduced connectivity between the basal ganglia and the motor cortex, which correlates with the severity of motor symptoms like bradykinesia and rigidity. These findings provide insights into the neural mechanisms underlying PD and suggest potential targets for therapeutic interventions (Fox & Greicius, 2018).

In addition to studying motor networks, fMRI has also been used to explore the cognitive deficits associated with Parkinson’s Disease. Many PD patients experience cognitive impairments, including difficulties with executive functions, memory, and attention. fMRI studies have revealed that these cognitive deficits are linked to altered connectivity in brain networks involved in cognition, such as the fronto-parietal network and the default mode network. By understanding these changes in brain connectivity, researchers can develop more effective strategies to address the cognitive symptoms of PD.

Another important application of fMRI in PD research is the assessment of therapeutic interventions. For example, deep brain stimulation (DBS) is a common treatment for PD that involves implanting electrodes in the brain to modulate neural activity. fMRI has been used to study the effects of DBS on brain activity and connectivity, providing valuable information about how this treatment alleviates motor symptoms. fMRI studies have shown that DBS can restore functional connectivity in motor networks, leading to improvements in movement control. This information is crucial for optimizing DBS settings and improving patient outcomes.

Moreover, fMRI can be used to monitor the effects of pharmacological treatments for PD. For instance, levodopa is the most commonly used medication for managing PD symptoms. fMRI studies have shown that levodopa administration leads to increased connectivity in motor networks, which correlates with improvements in motor function. By using fMRI to track these changes in brain activity, researchers can better understand how different treatments affect the brain and tailor therapies to individual patients.

Overall, fMRI is an invaluable tool in Parkinson’s Disease research, providing insights into the functional changes that occur in the brain as the disease progresses. It allows researchers to study the neural mechanisms underlying motor and cognitive symptoms, assess the effects of therapeutic interventions, and monitor disease progression. As fMRI technology continues to evolve, it is likely to play an even more significant role in the diagnosis and treatment of PD (Fox & Greicius, 2018).

Diffusion Tensor Imaging (DTI)

Diffusion tensor imaging (DTI) is a specialized form of magnetic resonance imaging (MRI) that focuses on the diffusion of water molecules in brain tissue, providing detailed information about the integrity of white matter tracts. White matter consists of bundles of axons that connect different regions of the brain, facilitating communication between them. In neurodegenerative diseases like Parkinson’s Disease, the integrity of these white matter tracts is often compromised, leading to disruptions in brain connectivity and function.

In Parkinson’s Disease, DTI has emerged as a valuable tool for studying changes in white matter integrity and their correlation with disease severity and progression. One of the key regions of interest in PD research is the substantia nigra, a brain structure that plays a critical role in movement control. The substantia nigra is one of the first regions to be affected in PD, with dopaminergic neurons in this area undergoing degeneration. DTI can detect changes in the microstructure of the substantia nigra, providing insights into the extent of neuronal loss and its impact on motor function.

Studies using DTI have shown that PD patients exhibit reduced fractional anisotropy (FA) in the substantia nigra and other brain regions, indicating a loss of white matter integrity. FA is a measure of the directional coherence of water diffusion in white matter tracts; lower FA values suggest disruptions in the microstructure of these tracts. The degree of FA reduction has been correlated with the severity of motor symptoms in PD, such as bradykinesia and rigidity, making it a potential biomarker for disease progression (Zhang et al., 2015).

In addition to studying the substantia nigra, DTI has also been used to examine other brain regions involved in PD, such as the corpus callosum, the basal ganglia, and the thalamus. Changes in white matter integrity in these regions have been linked to both motor and non-motor symptoms of PD, including cognitive impairments and mood disorders. By identifying these changes, DTI provides valuable information about the neural basis of these symptoms and helps guide the development of targeted therapies.

DTI has also been used in longitudinal studies to monitor the progression of Parkinson’s Disease over time. By repeatedly imaging patients at different stages of the disease, researchers can track changes in white matter integrity and correlate them with clinical outcomes. This approach allows for a better understanding of the natural history of PD and the factors that influence its progression. It also helps identify potential early markers of disease that could be used to predict disease onset and progression in at-risk individuals.

Overall, diffusion tensor imaging is a powerful tool in Parkinson’s Disease research, providing detailed insights into the structural changes that occur in the brain as the disease progresses. By studying changes in white matter integrity, DTI helps researchers understand the neural mechanisms underlying both motor and non-motor symptoms of PD and contributes to the development of more effective diagnostic and therapeutic strategies (Zhang et al., 2015).

Positron Emission Tomography (PET)

Positron emission tomography (PET) is a highly specialized imaging technique that uses radioactive tracers to visualize metabolic processes and neurotransmitter systems in the brain. PET is particularly valuable in Parkinson’s Disease research because it allows researchers to study the dopaminergic system, which is heavily impacted by the disease. Dopamine, a neurotransmitter that plays a crucial role in movement control, is produced in the substantia nigra and released into the striatum, where it facilitates communication between neurons. In PD, the degeneration of dopaminergic neurons in the substantia nigra leads to a significant reduction in dopamine levels, resulting in the characteristic motor symptoms of the disease.

One of the most common applications of PET in PD research is the use of radiotracers that bind to dopamine transporters (DAT) or dopamine receptors. DAT is a protein that regulates the reuptake of dopamine from the synaptic cleft back into the presynaptic neuron, and its density reflects the integrity of dopaminergic neurons. PET imaging with [^11C]- or [^18F]-labeled DAT tracers, such as [^11C]-PE2I or [^18F]-FP-CIT, can measure the distribution and density of DAT in the brain. Reduced DAT binding in the striatum is a hallmark of PD and correlates with the severity of motor symptoms, making DAT imaging a valuable tool for both diagnosis and disease monitoring (Politis, 2014).

In addition to DAT imaging, PET can also be used to study dopamine synthesis and receptor binding. For example, PET imaging with [^18F]-fluorodopa (FDOPA) allows researchers to measure the synthesis of dopamine in the brain. FDOPA is taken up by dopaminergic neurons and converted to dopamine, and its uptake reflects the functional status of these neurons. Reduced FDOPA uptake in the striatum is indicative of dopaminergic neuron loss and is commonly observed in PD patients. Similarly, PET imaging with radiotracers that bind to dopamine receptors, such as [^11C]-raclopride, can assess the availability of dopamine receptors in the brain, providing additional information about the dopaminergic system.

Beyond the dopaminergic system, PET imaging is also being used to explore other molecular targets involved in Parkinson’s Disease, such as alpha-synuclein and tau. Alpha-synuclein is a protein that aggregates in the brains of PD patients, contributing to neurodegeneration. Efforts are ongoing to develop PET tracers that can specifically bind to alpha-synuclein aggregates, allowing for their visualization in vivo. While still in the experimental stages, alpha-synuclein imaging holds promise as a biomarker for early diagnosis and monitoring disease progression.

Tau imaging is another area of active research in PD. Tau proteins form neurofibrillary tangles in the brain, which are primarily associated with Alzheimer’s Disease but are also present in some cases of PD, particularly in cases with overlapping pathology. PET imaging with tau tracers, such as [^18F]-AV-1451, is being explored as a potential biomarker for PD, especially in patients with cognitive impairment where tau pathology may contribute to the clinical picture.

Overall, PET is an indispensable tool in Parkinson’s Disease research, providing detailed insights into the dopaminergic system and other molecular targets involved in the disease. By visualizing these processes in vivo, PET imaging helps researchers understand the pathophysiology of PD, aids in the development of new diagnostic and therapeutic strategies, and provides valuable biomarkers for monitoring disease progression (Politis, 2014).

Single Photon Emission Computed Tomography (SPECT)

Single photon emission computed tomography (SPECT) is a nuclear imaging technique similar to positron emission tomography (PET), but it uses gamma rays to create three-dimensional images of the brain. SPECT is widely used in Parkinson’s Disease research and clinical practice, particularly for imaging the dopaminergic system. Like PET, SPECT can visualize the distribution and density of dopamine transporters (DAT) in the brain, providing critical information about the integrity of dopaminergic neurons.

One of the most common radiotracers used in SPECT imaging for PD is [^123I]-ioflupane (DaTSCAN), which binds to DAT. DaTSCAN is approved for clinical use in many countries and is frequently used to help diagnose PD and differentiate it from other movement disorders, such as essential tremor and drug-induced parkinsonism. In patients with PD, DaTSCAN imaging typically shows reduced DAT binding in the striatum, reflecting the loss of dopaminergic neurons in the substantia nigra. This reduction in DAT binding is often asymmetric, with more pronounced loss on the side of the brain opposite to the side of the body where symptoms are most severe (Bohnen & Albin, 2017).

SPECT imaging is also used to study other aspects of brain function in PD, such as cerebral blood flow and neurotransmitter receptor distribution. For example, SPECT with [^123I]-iodobenzamide (IBZM) can visualize dopamine D2 receptors in the brain, providing insights into receptor availability and function. This is particularly useful for distinguishing PD from atypical parkinsonian syndromes, such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), which may show different patterns of receptor binding.

In addition to dopamine-related imaging, SPECT can also be used to assess cerebral blood flow. SPECT imaging with [^99mTc]-hexamethylpropyleneamine oxime (HMPAO) or [^123I]-iodoamphetamine (IMP) can visualize regional cerebral blood flow, which may be altered in PD due to changes in brain metabolism and neuronal activity. Studies have shown that PD patients often exhibit reduced blood flow in the frontal and parietal lobes, which may be associated with cognitive deficits and other non-motor symptoms of the disease.

SPECT imaging has several advantages in PD research and clinical practice. It is widely available, relatively inexpensive compared to PET, and provides valuable information about the dopaminergic system and cerebral blood flow. However, SPECT also has some limitations. It has lower spatial resolution compared to PET, which means that it may not detect very small or subtle changes in brain structure or function. Additionally, the interpretation of SPECT images can be challenging, particularly in cases with overlapping pathology or atypical clinical presentations.

Despite these limitations, SPECT remains an important tool in Parkinson’s Disease research, particularly for studying the dopaminergic system and assessing cerebral blood flow. It provides valuable information that can aid in the diagnosis of PD, monitor disease progression, and evaluate the effects of therapeutic interventions. As new radiotracers and imaging techniques continue to be developed, the role of SPECT in PD research is likely to expand, offering even more insights into the pathophysiology of the disease (Bohnen & Albin, 2017).

Ultrasound Imaging

Transcranial sonography (TCS) is a non-invasive ultrasound imaging technique that has gained recognition as a valuable tool in Parkinson’s Disease research and clinical practice. Unlike other imaging modalities such as MRI and PET, which require complex and expensive equipment, TCS is relatively simple, inexpensive, and widely accessible. It is particularly useful for detecting structural changes in the brain, such as hyperechogenicity of the substantia nigra, which is a hallmark of PD.

In Parkinson’s Disease, one of the most consistent findings on TCS is increased echogenicity (brightness) of the substantia nigra. This hyperechogenicity is thought to reflect increased iron content in this brain region, which is associated with the degeneration of dopaminergic neurons. Studies have shown that TCS can detect substantia nigra hyperechogenicity in the majority of PD patients, making it a valuable diagnostic tool. Moreover, TCS can differentiate PD from other movement disorders, such as essential tremor and dystonia, which typically do not show this pattern of hyperechogenicity (Berg, Godau, & Walter, 2011).

In addition to diagnosing PD, TCS can also be used to identify individuals at risk of developing the disease. Research has shown that substantia nigra hyperechogenicity is present in a significant proportion of healthy individuals who later go on to develop PD. This suggests that TCS could be used as a screening tool to identify at-risk individuals for closer monitoring or early intervention. Furthermore, TCS has been used to study the progression of PD, with some studies indicating that the extent of substantia nigra hyperechogenicity correlates with disease severity and progression.

Another application of TCS in PD research is the assessment of other brain regions involved in the disease. For example, TCS can be used to visualize the lenticular nucleus, which is often hyperechogenic in patients with atypical parkinsonian syndromes such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). This helps in differentiating these conditions from PD, which typically does not show lenticular nucleus hyperechogenicity. Additionally, TCS can be used to assess the third ventricle width, which may be enlarged in patients with advanced PD or in those with atypical parkinsonian syndromes.

TCS also has potential applications in monitoring the effects of therapeutic interventions in PD. For example, some studies have explored the use of TCS to assess changes in substantia nigra echogenicity following deep brain stimulation (DBS) or medication treatment. While the clinical significance of these changes is still under investigation, TCS offers a non-invasive and repeatable method for tracking disease-related changes in the brain.

Despite its advantages, TCS does have some limitations. The quality of TCS images can be affected by the patient's skull thickness, which can vary widely between individuals and can sometimes limit the ability to obtain clear images. Additionally, TCS is primarily a research tool at present, and its use in routine clinical practice is still limited, particularly outside of specialized centers. Nevertheless, TCS represents a promising and accessible imaging modality that can complement other imaging techniques in the diagnosis and management of Parkinson’s Disease (Berg, Godau, & Walter, 2011).

Emerging Imaging Technologies

As the field of neuroimaging advances, several emerging imaging technologies show great promise for enhancing Parkinson’s Disease (PD) research. These technologies are being explored for their potential to provide higher resolution images, more detailed molecular information, and better monitoring of disease progression. Among the most promising emerging technologies are optical coherence tomography (OCT), photoacoustic imaging, and novel molecular imaging techniques.

Optical Coherence Tomography (OCT): OCT is a non-invasive imaging technique commonly used in ophthalmology to obtain high-resolution cross-sectional images of the retina. In recent years, OCT has been explored as a potential tool for PD research because retinal changes may reflect neurodegenerative processes occurring in the brain. The retina is an extension of the central nervous system, and alterations in retinal nerve fiber layer thickness have been observed in PD patients. These changes may serve as biomarkers for early diagnosis and disease progression. OCT is particularly appealing because it is a quick, non-invasive, and relatively inexpensive technique that can be easily integrated into clinical practice. Ongoing research is investigating the potential of OCT to detect retinal changes that correlate with the severity of motor and non-motor symptoms in PD, offering a novel approach to monitoring the disease (Satue et al., 2014).

Photoacoustic Imaging: Another emerging technology with potential applications in PD is photoacoustic imaging, which combines optical and ultrasound imaging to provide detailed information about the structure and function of tissues. Photoacoustic imaging is particularly well-suited for visualizing vascular structures and measuring oxygen saturation levels in tissues. In PD research, this technology could be used to study changes in brain vasculature, such as alterations in cerebral blood flow and oxygenation, which are thought to play a role in the disease’s pathophysiology. Additionally, photoacoustic imaging could be used to monitor the effects of treatments aimed at improving cerebral blood flow or reducing oxidative stress, providing valuable insights into the efficacy of new therapeutic interventions (Wang & Hu, 2012).

Novel Molecular Imaging Techniques and Surrogate Biomarkers Under Development in PD

Advancements in molecular imaging are opening new avenues for Parkinson's Disease (PD) research, offering detailed insights into the biochemical processes and protein interactions that underpin neurodegeneration. These novel imaging techniques are particularly valuable for understanding the complex pathophysiology of PD, aiding in early diagnosis, monitoring disease progression, and developing targeted therapeutic strategies. Several imaging biomarkers are under development, each providing unique insights into PD and the effectiveness of potential treatments.

Alpha-Synuclein Imaging

One of the most promising developments in molecular imaging is the visualization of alpha-synuclein, a protein that aggregates in the brains of individuals with PD. Alpha-synuclein pathology is a hallmark of PD and plays a critical role in neurodegeneration. Researchers are working on developing PET tracers that can specifically bind to alpha-synuclein aggregates, allowing for in vivo imaging of these deposits. Alpha-synuclein imaging could revolutionize PD diagnosis by enabling earlier detection of the disease, even before motor symptoms appear. Additionally, it could monitor disease progression and assess the efficacy of therapies aimed at reducing or preventing alpha-synuclein aggregation, thus serving as a powerful surrogate biomarker in clinical trials (Eberling, Dave, & Frasier, 2013).

Tau Imaging

Tau proteins, which form neurofibrillary tangles in the brain, are primarily associated with Alzheimer's Disease but are also present in certain PD cases, particularly those with cognitive impairments or overlapping pathologies. PET imaging with tau-specific tracers is being explored as a potential biomarker for differentiating PD from other neurodegenerative diseases and understanding the role of tau in PD. Tau imaging could offer insights into the heterogeneity of PD, especially in cases where cognitive decline is prominent. It could also be a surrogate marker in clinical trials focused on treatments targeting tau pathology, helping evaluate their effectiveness in reducing tau-related neurodegeneration (Chien et al., 2014).

Dopamine Transporter Imaging (DAT Imaging)

Dopamine transporter (DAT) imaging is a well-established technique used to measure the density of dopamine transporters in the brain, which are significantly reduced in PD. This technique, primarily performed using SPECT or PET, provides direct measures of dopaminergic neuron loss, making it valuable for both diagnosing PD and monitoring its progression. In clinical trials, DAT imaging is used as a surrogate marker to track the efficacy of neuroprotective treatments aimed at preserving dopaminergic neurons. Its ability to detect early dopaminergic dysfunction makes it a powerful tool for identifying individuals at risk for PD and evaluating early interventions (Politis, 2014).

Neuroinflammation Imaging

Neuroinflammation is increasingly recognized as a key factor in PD progression. Activated microglia, the immune cells of the central nervous system, contribute to this process. PET imaging with tracers that bind to markers of microglial activation, such as the translocator protein (TSPO), allows for in vivo visualization of neuroinflammation. This technique provides insights into the role of inflammation in PD and could serve as a surrogate biomarker for assessing the efficacy of anti-inflammatory therapies. Monitoring neuroinflammation before and after treatment is crucial for refining therapeutic strategies and selecting patients who are most likely to benefit from these interventions (Cosenza-Nashat et al., 2009).

Iron Deposition Imaging

Iron accumulation in the substantia nigra and other brain regions is a hallmark of PD and contributes to neurodegeneration through oxidative stress. Advanced MRI techniques, such as susceptibility-weighted imaging (SWI) and quantitative susceptibility mapping (QSM), are used to quantify iron levels in the brain. Iron deposition imaging not only helps understand PD pathophysiology but also serves as a tool for monitoring the effects of therapies aimed at reducing oxidative stress or modulating iron metabolism. This imaging modality could be particularly valuable for identifying individuals at higher risk for rapid disease progression and for assessing early therapeutic intervention outcomes (Schwarz et al., 2018).

Mitochondrial Dysfunction Imaging

Mitochondrial dysfunction is a central feature of PD, leading to increased oxidative stress and neuronal death. Novel imaging techniques are being developed to assess mitochondrial function in vivo. For instance, PET tracers that measure the activity of mitochondrial enzymes, such as cytochrome c oxidase, offer a direct measure of mitochondrial health. This approach could serve as a surrogate biomarker for early diagnosis and treatment monitoring, particularly for therapies targeting mitochondrial function. Imaging mitochondrial dysfunction could also help identify patients with specific mitochondrial profiles, leading to more personalized treatment approaches (Cardoso et al., 2020).

Synaptic Density Imaging

Loss of synaptic connections is a key feature of neurodegeneration in PD, contributing to both motor and cognitive symptoms. Imaging synaptic density using novel PET tracers that bind to synaptic vesicle proteins, such as synaptic vesicle glycoprotein 2A (SV2A), could provide a direct measure of neurodegeneration. This approach allows researchers to monitor synaptic loss over time and evaluate the impact of treatments aimed at preserving or restoring synaptic function. Synaptic density imaging could also help identify early changes that precede the onset of symptoms, offering new opportunities for early intervention (Finnema et al., 2016).

Glucose Metabolism Imaging

Alterations in brain glucose metabolism are observed in PD and can provide valuable insights into disease progression and treatment effects. PET imaging with [^18F]-fluorodeoxyglucose (FDG) is a well-established method for measuring cerebral glucose metabolism, reflecting neuronal activity. In PD, FDG-PET has shown patterns of hypometabolism in specific brain regions, such as the posterior parietal cortex and frontal lobes, which are associated with cognitive impairments and other non-motor symptoms. Glucose metabolism imaging could serve as a surrogate biomarker for assessing the effectiveness of treatments targeting metabolic pathways or for evaluating interventions aimed at improving cognitive function in PD (Politis, 2014).

Blood-Brain Barrier Integrity

The integrity of the blood-brain barrier (BBB) is increasingly recognized as a critical factor in PD pathophysiology. Disruption of the BBB allows harmful substances to enter the brain, contributing to neuroinflammation and neurodegeneration. Advanced MRI techniques, such as dynamic contrast-enhanced MRI (DCE-MRI), are being explored to assess BBB integrity in vivo. Imaging the BBB could serve as a biomarker for identifying patients with increased permeability, who may be at greater risk for rapid disease progression. Monitoring BBB integrity could also be useful in evaluating treatments aimed at stabilizing or repairing the BBB, offering a novel approach to slowing PD progression (van Vliet et al., 2020).

Imaging in Clinical Trials: Enhancing Phase 2 and Phase 3 Studies

The Role of Imaging in Clinical Trials

Imaging techniques have become indispensable tools in clinical trials for Parkinson's Disease (PD), especially in Phase 2 and Phase 3 studies, where they play a critical role in assessing the efficacy and safety of new treatments. These phases are pivotal for determining whether a treatment has a significant therapeutic benefit and for confirming its safety profile. In this context, imaging provides objective, quantifiable data on brain structure and function that can be used to track disease progression and response to therapy.

During Phase 2 trials, imaging is often employed to gather preliminary data on the biological effects of a treatment. For instance, MRI can be used to detect changes in brain volume or white matter integrity, while PET can measure alterations in dopamine transporter levels or other biomarkers associated with PD. These imaging outcomes can help determine whether a drug is affecting the brain in the desired manner and can guide dosage adjustments before moving into larger Phase 3 trials (Mahlknecht et al., 2017).

In Phase 3 trials, imaging becomes even more crucial as it helps to solidify the evidence of a treatment's efficacy. Large-scale studies often require robust biomarkers that can reliably demonstrate treatment effects across diverse populations. Imaging biomarkers, such as changes in dopamine transporter binding as observed through PET scans, provide a consistent and objective measure of treatment impact, complementing clinical assessments of motor and cognitive function. This dual approach of using clinical and imaging endpoints ensures that the trials provide comprehensive data on both symptomatic relief and underlying disease modification (Politis, 2014).

Use of Surrogate Markers in Clinical Trials

Surrogate markers derived from imaging data are increasingly being utilized in PD clinical trials as predictive tools for clinical outcomes. These markers, such as dopamine transporter binding changes detected through PET, serve as early indicators of a treatment's efficacy, often preceding observable clinical improvements. The adoption of such surrogate markers is crucial because they allow for the early identification of promising therapies, potentially accelerating the drug development process.

The use of surrogate markers can also reduce the need for extensive clinical evaluations, which are often time-consuming and burdensome for patients. For example, instead of relying solely on repeated clinical assessments to gauge treatment efficacy, researchers can use PET imaging to track changes in dopamine transporter levels, providing a more direct and potentially earlier measure of drug impact. This approach not only enhances the efficiency of clinical trials but also offers a way to monitor disease progression more accurately, especially in the early stages of PD when clinical symptoms may be subtle or variable (Politis, 2014).

However, the development of reliable and specific surrogate markers is not without challenges. It requires a deep understanding of the disease's pathophysiology and the ability to correlate imaging findings with long-term clinical outcomes. Ongoing research is focused on identifying and validating new surrogate markers that can more accurately predict the effectiveness of emerging therapies, thereby streamlining the clinical trial process and improving patient outcomes.

Balancing Sensitivity, Specificity, and Patient Burden

One of the primary challenges in using imaging in clinical trials is balancing the need for sensitive and specific data with the practicalities of study design. While advanced imaging techniques such as PET and MRI offer detailed and accurate insights into brain function and structure, they also require sophisticated equipment and can be both time-consuming and costly. Additionally, the requirement for repeated imaging sessions over the course of a trial can place a significant burden on patients, particularly those with advanced PD who may find frequent visits and lengthy procedures physically demanding.

To address these challenges, trial designers must carefully consider the frequency and timing of imaging sessions. The goal is to obtain enough data to reliably detect treatment effects while minimizing the inconvenience and discomfort for participants. For instance, incorporating fewer, but more strategically timed, imaging sessions might provide sufficient data without overburdening patients. Alternatively, newer imaging techniques that require less time or can be performed in a more patient-friendly manner could be adopted to reduce the overall burden (Fox & Greicius, 2018).

Moreover, researchers are exploring the use of portable or less invasive imaging technologies, such as transcranial sonography, which could be conducted in a clinic setting with minimal disruption to the patient’s routine. Balancing the sensitivity and specificity of imaging data with patient comfort and study feasibility is essential for the success of clinical trials, as it directly impacts patient recruitment, retention, and the overall quality of the data collected.

Challenges in Imaging for Parkinson’s Disease

Despite the numerous advancements in imaging technologies, several challenges persist in the application of these tools to Parkinson’s Disease research. One of the most significant challenges is the high cost associated with advanced imaging studies. Techniques such as PET and high-resolution MRI require expensive equipment, specialized facilities, and highly trained personnel. These costs can be prohibitive, particularly in large-scale studies or in settings with limited resources. As a result, access to advanced imaging technologies may be restricted, potentially limiting the generalizability of research findings across different populations (Mahlknecht et al., 2017).

Another major challenge is the need for standardized imaging protocols. Variability in imaging techniques, such as differences in scanner calibration, image acquisition parameters, and analysis methods, can lead to inconsistencies in data across studies. This variability makes it difficult to compare results from different research centers or to combine data in meta-analyses, ultimately hindering the advancement of knowledge in the field. Efforts are ongoing to establish standardized protocols and to develop guidelines that ensure consistency in imaging studies of PD, but this remains an area of active research and development.

The complexity of interpreting imaging data also poses a challenge. Advanced imaging techniques generate large amounts of data, which must be carefully analyzed to extract meaningful insights. This requires sophisticated software tools and expertise in neuroimaging, as well as an understanding of the biological significance of the findings. The interpretation of imaging data can be particularly challenging in PD due to the disease’s heterogeneity; different patients may show varying patterns of brain changes, making it difficult to draw general conclusions. Moreover, imaging findings must be correlated with clinical outcomes to establish their relevance, which adds another layer of complexity to the research (Schwarz et al., 2018).

Finally, there is the challenge of ensuring that imaging studies are designed in a way that is ethical and respectful of patients’ needs and preferences. Imaging studies often involve repeated exposure to imaging procedures, some of which may involve radiation or other risks. It is essential to balance the potential benefits of the research with the need to minimize risks and discomfort for participants, particularly in vulnerable populations such as those with advanced PD.

Future Directions in Imaging Research

The future of imaging research in Parkinson’s Disease is full of potential, driven by ongoing developments in technology and methodology. One of the most promising areas of research is the integration of artificial intelligence (AI) and machine learning with imaging data analysis. AI techniques, such as deep learning, are being increasingly applied to neuroimaging data to enhance the accuracy and efficiency of image analysis. These techniques can automatically detect patterns and anomalies in large imaging datasets, offering new ways to diagnose PD and monitor disease progression with greater precision than ever before. By improving the ability to analyze complex imaging data, AI has the potential to revolutionize the field, making it possible to identify subtle changes in brain structure and function that may not be detectable with traditional analysis methods (Schwarz et al., 2018).

Another exciting development is the integration of multimodal imaging techniques, which combine data from different imaging modalities to provide a more comprehensive understanding of the disease. For example, combining structural MRI with functional MRI (fMRI) and PET can offer a more complete picture of the brain’s anatomy, function, and biochemistry. This approach can help identify how different aspects of brain pathology interact in PD and can lead to more targeted and effective treatments. Multimodal imaging is also being explored as a way to improve the accuracy of early diagnosis by capturing a broader range of disease-related changes in the brain (Mahlknecht et al., 2017).

The ongoing development of new imaging biomarkers is another key area of focus. Researchers are working to identify and validate biomarkers that can more accurately predict disease progression and response to treatment. These biomarkers could be used to stratify patients in clinical trials, ensuring that those who are most likely to benefit from a particular therapy are included. Additionally, new biomarkers could enable earlier diagnosis and intervention, potentially slowing or even halting the progression of PD.

Finally, there is growing interest in the application of imaging techniques to study non-motor symptoms of PD, such as cognitive impairment, mood disorders, and sleep disturbances. These symptoms can have a significant impact on patients’ quality of life, but they are often less well understood than the motor symptoms of the disease. Imaging studies that focus on the brain regions and networks involved in these non-motor symptoms could provide new insights into their underlying mechanisms and lead to the development of more effective treatments.

Ethical Considerations in Imaging Research

Ethical considerations are paramount in imaging research, particularly when studies involve vulnerable populations such as individuals with Parkinson’s Disease. One of the key ethical issues is ensuring informed consent. Participants must be fully informed about the nature of the imaging procedures, the potential risks and benefits, and their rights as research subjects. This includes providing clear information about any radiation exposure associated with PET or SPECT imaging, as well as the potential discomfort or inconvenience of MRI procedures. Researchers must ensure that participants understand this information and provide their consent freely, without any coercion (Berg, Godau, & Walter, 2011).

Another critical ethical consideration is protecting the privacy and confidentiality of participants’ data. Imaging studies generate large amounts of sensitive data, including detailed images of participants’ brains. This data must be securely stored and protected to prevent unauthorized access or breaches of confidentiality. Researchers must also consider the potential implications of incidental findings—unexpected abnormalities detected during imaging that may have clinical significance. Participants should be informed in advance about how such findings will be handled, and appropriate follow-up care should be provided if necessary.

The potential for incidental findings also raises questions about the ethical responsibilities of researchers. For example, if an incidental finding suggests a serious but treatable condition, researchers may have an obligation to inform the participant and refer them for appropriate medical care. However, this must be balanced with respect for the participant’s autonomy and their right to decide whether they want to receive such information.

Finally, ethical research practices must take into account the burden of participation on individuals with PD, who may already be dealing with significant physical and emotional challenges. Researchers should strive to minimize the number of procedures and visits required, reduce the duration of imaging sessions, and provide support to help participants manage any discomfort or stress associated with the study. By addressing these ethical considerations, researchers can ensure that imaging studies are conducted in a manner that respects the rights and well-being of participants while advancing scientific knowledge.

Patient Perspectives on Imaging

Understanding patient perspectives is crucial for the successful implementation of imaging techniques in clinical practice and research. Patients’ experiences and preferences regarding imaging procedures can significantly influence their willingness to participate in studies and their overall satisfaction with their care. It is important for researchers and clinicians to consider these perspectives when designing studies and implementing imaging protocols.

One of the primary concerns for patients undergoing imaging procedures is the physical and emotional discomfort associated with these tests. MRI, for example, can be challenging for individuals who experience claustrophobia or anxiety, as the procedure requires lying still in a confined space for an extended period. Similarly, PET and SPECT imaging involve the injection of radioactive tracers, which can be unsettling for some patients. Addressing these concerns through clear communication, offering comfort measures, and providing psychological support can help alleviate patient anxiety and improve their overall experience (Satue et al., 2014).

Patients also value clear and transparent communication about the purpose and potential outcomes of imaging studies. They want to understand how the imaging results will be used in their care and what the potential risks and benefits are. Providing detailed explanations and involving patients in decision-making can help build trust and ensure that they feel informed and empowered in their healthcare journey.

Another important consideration is the impact of imaging studies on patients’ daily lives. Frequent visits to imaging centers, long wait times, and the need to take time off work or arrange transportation can all be burdensome for patients with PD, who may already be dealing with significant physical limitations. Researchers and clinicians should consider ways to minimize these burdens, such as scheduling imaging sessions at convenient times, reducing the number of required visits, and providing transportation assistance if needed.

Finally, patients appreciate when their feedback is solicited and taken into account. Incorporating patient perspectives into the design and implementation of imaging studies can lead to more patient-centered research and care. This might involve conducting focus groups or surveys to gather input on imaging protocols, or establishing patient advisory boards to provide ongoing feedback and guidance.

Conclusion

Advanced imaging techniques have dramatically transformed Parkinson’s Disease research and clinical practice, offering unprecedented insights into the structural, functional, and molecular changes associated with the disease. These techniques are essential for diagnosing, monitoring, and treating PD, providing objective and reliable data that can significantly enhance the design and outcomes of clinical trials. As imaging technologies continue to evolve, they hold great promise for furthering our understanding of PD and improving patient care.

The development of surrogate markers, the balance between data sensitivity and patient burden, and the integration of artificial intelligence and multimodal imaging are likely to be key areas of focus in the coming years. These advancements have the potential to revolutionize the way we diagnose and treat PD, leading to earlier detection, more personalized therapies, and better outcomes for patients.

However, the success of imaging research and its application in clinical practice will depend on our ability to address the challenges that remain. This includes overcoming the high costs and technical complexities of imaging studies, standardizing protocols, and ensuring that data interpretation is accurate and meaningful. Ethical considerations and patient perspectives must also be at the forefront of research and clinical practice, ensuring that the benefits of imaging are realized in a way that respects the rights and well-being of individuals with PD.

In conclusion, the future of Parkinson’s Disease research is bright, with advanced imaging techniques leading the way. By continuing to innovate and address the challenges of imaging research, we can look forward to a future where PD is better understood, more effectively treated, and, ultimately, prevented.

FAQs

What are the most commonly used imaging techniques in Parkinson’s Disease research?

The most commonly used imaging techniques in Parkinson’s Disease research include MRI, fMRI, DTI, PET, and SPECT. These modalities provide detailed insights into brain structure and function, aiding in the diagnosis and monitoring of PD.

How does MRI contribute to the diagnosis of Parkinson’s Disease?

MRI is used to detect structural changes in the brain, such as atrophy in specific regions, which are associated with Parkinson’s Disease. Advanced MRI techniques like fMRI and DTI offer additional insights into brain function and connectivity, making MRI a valuable tool in early diagnosis.

What is the role of PET scans in Parkinson’s Disease research?

PET scans are used to study the dopaminergic system, which is significantly affected in Parkinson’s Disease. PET imaging provides valuable information on the distribution and density of dopamine receptors and can also visualize other molecular targets, such as alpha-synuclein and tau.

How do emerging imaging technologies impact Parkinson’s Disease research?

Emerging imaging technologies, such as optical coherence tomography (OCT) and photoacoustic imaging, are being explored for their potential to provide high-resolution images of brain structures and monitor disease progression, offering new avenues for PD research.

What are the challenges in using imaging techniques for Parkinson’s Disease?

Challenges include the high cost of imaging studies, the need for standardized protocols, and the complexity of interpreting imaging data. Addressing these challenges is crucial for advancing PD research.

How do patients perceive the use of imaging in Parkinson’s Disease research?

Patients generally have positive attitudes towards imaging but may have concerns about the risks and discomfort associated with certain procedures. Addressing these concerns is essential for patient-centered research.

References

Berg, D., Godau, J., & Walter, U. (2011). Transcranial sonography in movement disorders. The Lancet Neurology, 10(11), 1040-1045.

Bohnen, N. I., & Albin, R. L. (2017). The cholinergic system and Parkinson disease. Behavioural Brain Research, 221, 564-573.

Brooks, D. J. (2016). Imaging approaches to Parkinson disease. Journal of Nuclear Medicine, 57(1), 3-4.

Cardoso, S., Empadinhas, N., & Santos, M. S. (2020). Mitochondria-driven neuroinflammation and neurodegenerative diseases: Lessons from Parkinson's Disease. Biochemical Pharmacology, 175, 113929.

Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Xia, C., ... & Fodero-Tavoletti, M. T. (2014). Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. Journal of Alzheimer's Disease, 38(1), 171-184.

Cosenza-Nashat, M., Zhao, M. L., Suh, H. S., Morgan, J., Natividad, R., Morgello, S., ... & Lee, S. C. (2009). Expression of the translocator protein of 18 kDa by microglia in human neurological diseases. Neuron Glia Biology, 5(3-4), 307-315.

Eberling, J. L., Dave, K. D., & Frasier, M. A. (2013). α-Synuclein imaging: A critical need for Parkinson's disease research. Journal of Parkinson's Disease, 3(4), 565-567.

Finnema, S. J., Nabulsi, N. B., Eid, T., Detyniecki, K., Lin, S. F., Chen, M. K., ... & Ding, Y. S. (2016). Imaging synaptic density in the living human brain. Science Translational Medicine, 8(348), 348ra96.

Fox, M. D., & Greicius, M. (2018). Clinical applications of resting state functional connectivity. Frontiers in Systems Neuroscience, 4, 19.

Mahlknecht, P., Krismer, F., Seppi, K., Poewe, W., & Wenning, G. K. (2017). Imaging biomarkers for Parkinson's disease. Nature Reviews Neurology, 13(2), 74-86.

Politis, M. (2014). Neuroimaging in Parkinson disease: From research setting to clinical practice. Nature Reviews Neurology, 10(12), 708-722.

Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., ... & Litvan, I. (2015). MDS clinical diagnostic criteria for Parkinson's disease. Movement Disorders, 30(12), 1591-1601.

Satue, M., Obis, J., Rodrigo, M. J., Otin, S., Fuertes, I., Vilades, E., ... & Garcia-Martin, E. (2014). Optical coherence tomography as a biomarker for diagnosis, progression, and prognosis of neurodegenerative diseases. Journal of Ophthalmology, 2014.

Schwarz, S. T., Afzal, M., Morgan, P. S., Bajaj, N., Gowland, P. A., & Auer, D. P. (2018). The ‘swallow tail’ appearance of the healthy nigrosome–a new accurate test of Parkinson's disease: A case-control and retrospective cross-sectional MRI study at 3T. PloS one, 9(4), e93814.

van Vliet, E. A., Ndode-Ekane, X. E., & Gorter, J. A. (2020). Blood-brain barrier pathology after epilepsy surgery: An overlooked target? Frontiers in Cellular Neuroscience, 14, 47.

Wang, L. V., & Hu, S. (2012). Photoacoustic tomography: In vivo imaging from organelles to organs. Science, 335(6075), 1458-1462.

Zhang, Y., Wu, I. W., Buckley, S., Coffey, C. S., Foster, E., Mendick, S., ... & Parkinson Progression Marker Initiative. (2015). Diffusion tensor imaging of the nigrostriatal fibers in Parkinson's disease. Movement Disorders, 30(9), 1229-1236.